SCHEMBL1428217

SCHEMBL1428217

Fc1ccc(-c2nc3ccc(F)cn3c2CNc2nc(F)cc(F)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.53
GABRB2 P47870 3/20 0.53
NR1H4 Q96RI1 1/20 0.45
SIRT5 Q9NXA8 1/20 0.44
SLC2A1 P11166 2/20 0.43
SLC2A3 P11169 1/20 0.42
SLC2A4 P14672 1/20 0.42
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
HDAC1 Q13547 2/20 0.39
TRPA1 O75762 1/20 0.39
PRNP P04156 1/20 0.38
CYP19A1 P11511 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1430115 0.90 NR1H4 (0.57) GABRA1GABRB2NR1H4SLC2A1ALDH1A1
SCHEMBL1430096 0.90 SIRT5 (0.56) GABRA1GABRB2NR1H4SIRT5SLC2A1
SCHEMBL1430054 0.82 SLC2A1 (0.49) GABRB2SIRT5SLC2A1ALDH1A1KDM4E
SCHEMBL1430828 0.78 KMT2A (0.48) SLC2A1ALDH1A1MAPTKDM4EGAA
SCHEMBL1427821 0.77 SIRT5 (0.51) GABRA1GABRB2NR1H4SIRT5SLC2A1
SCHEMBL1427715 0.77 NR1H4 (0.52) GABRA1GABRB2NR1H4SIRT5SLC2A3
SCHEMBL1430287 0.77 KDM4E (0.57) GABRA1GABRB2SLC2A1ALDH1A1MAPT
SCHEMBL1427447 0.77 SIRT5 (0.55) GABRA1GABRB2NR1H4SIRT5SLC2A1
Hydrochloric Acid SCHEMBL1433038 0.76 GABRA1 (0.59) GABRA1GABRB2NR1H4SIRT5SLC2A1
SCHEMBL1428065 0.74 SIRT5 (0.53) GABRA1GABRB2SIRT5SLC2A1SLC2A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
EP-2300470-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS Sepracor Inc. (US) 2011-03-30 EP disclosed
WO-2009143156-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SEPRACOR INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD GABRA1 817/4885GABRB2 1166/4885NR1H4 674/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD GABRA1 817/4885GABRB2 1166/4885NR1H4 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.